Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Acrc Studies LLC

Neither a doctor nor a teaching hospital

Research payments

$456,029

169 payments

Through program year 2024, Acrc Studies LLC is reported as receiving $456,029 in research payments, across 169 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $7,166 1
2023 Research $33,206 13
2022 Research $91,366 67
2021 Research $148,292 48
2020 Research $153,249 37
2019 Research $22,750 3

Breakdown

Who paid Research payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $139,161 79 payments
  2. Pfizer Inc. $87,823 22 payments
  3. Genentech, Inc. $67,089 15 payments
  4. Dermira, Inc. $34,913 3 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $25,680 4 payments
  6. Arena Pharmaceuticals, Inc. $22,327 20 payments
  7. Ucb SA $20,506 6 payments
  8. Janssen Research & Development, LLC $16,042 2 payments
  9. Vifor (International) Ltd. $12,150 5 payments
  10. Sanofi US Services Inc. $9,285 5 payments
Studies the money was for Research payments · program years 2019–2024
  1. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $112,182 58 payments
  2. Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $87,823 22 payments
  3. Transmission Study Household $67,089 15 payments
  4. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $34,913 3 payments
  5. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $26,979 21 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $20,506 6 payments
  7. A Multi Center Randomized Double blind Parallel group Placebo controlled Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants with Active Rheumatoid Arthritis Despite Standard Therapy $16,042 2 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $13,080 3 payments
  9. Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder $12,600 1 payment
  10. Diamond Pat-Cr-302 $12,150 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record